Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience

2020 ◽  
Vol 49 (3) ◽  
pp. 431-440 ◽  
Author(s):  
Thuy Tran ◽  
Justin Arnall ◽  
Donald C. Moore ◽  
Leslie Ward ◽  
Surabhi Palkimas ◽  
...  
2012 ◽  
Vol 28 (3) ◽  
pp. 157-161
Author(s):  
Rosline Hassan ◽  
Wan Aswani Wan Yusof ◽  
Nik Hazlina Nik Hussain ◽  
Wan Zaidah Abdullah

2016 ◽  
Vol 43 (01) ◽  
pp. 092-100
Author(s):  
Ana Kempfer ◽  
Juvenal Paiva ◽  
Analia Sanchez-Luceros ◽  
Emilse Bermejo ◽  
Roberto Chuit ◽  
...  

2017 ◽  
Vol 24 (6) ◽  
pp. 901-907 ◽  
Author(s):  
Zafer Şalcıoğlu ◽  
Cengiz Bayram ◽  
Hülya Şen ◽  
Gizem Ersoy ◽  
Gönül Aydoğan ◽  
...  

Congenital factor deficiencies (CFDs) refer to inherited deficiency of coagulation factors in the blood. A total of 481 patients with CFDs, who were diagnosed and followed at our Pediatric Hematology and Oncology Clinic between 1990 and 2015, were retrospectively evaluated. Of the 481 cases, 134 (27.8%) were hemophilia A, 38 (7.9%) were hemophilia B, 57 (11.8%) were von Willebrand disease (vWD), and 252 (52.3%) were rare bleeding disorders (RBDs). The median age of the patients at the time of diagnosis and at the time of the study was 4.1 years (range: 2 months to 20.4 years) and 13.4 years (range: 7 months to 31.3 years), respectively. The median duration of the follow-up time was 6.8 years (range: 2.5 months to 24.8 years). One hundred nineteen (47.2%) of 252 patients with RBDs were asymptomatic, 49 (41.1%) of whom diagnosed by family histories, 65 (54.6%) through preoperative laboratory studies, and 5 (4.2%) after prolonged bleeding during surgeries. Consanguinity rate for the RBDs was 47.2%. Prophylactic treatment was initiated in 80 patients, 58 of whom were hemophilia A, 7 were hemophilia B, 13 were RBDs, and 2 were vWD. Significant advances have been achieved during the past 2 decades in the treatment of patients with CFDs, particularly in patients with hemophilias. The rarity and clinical heterogeneity of RBDs lead to significant diagnostic challenges and improper management. In this regard, multinational collaborative efforts are needed with the hope that can improve the management of patients with RBDs.


2011 ◽  
Vol 37 (05) ◽  
pp. 560-567 ◽  
Author(s):  
Mariana Bonduel ◽  
Juan Frontroth ◽  
Mirta Hepner ◽  
Gabriela Sciuccati ◽  
Aurora Feliu-Torres ◽  
...  

Heliyon ◽  
2020 ◽  
Vol 6 (2) ◽  
pp. e03426 ◽  
Author(s):  
Valeria De Padua ◽  
Umberto Romeo ◽  
Cristina Santoro ◽  
Riccardo Bosco ◽  
Erminia Baldacci ◽  
...  

2016 ◽  
Vol 24 (1) ◽  
pp. 93-102
Author(s):  
Andrei Colită ◽  
Carmen Saguna ◽  
Andra Costache ◽  
Gabriela Borsaru ◽  
Raluca Manolache ◽  
...  

Abstract Acquired von Willebrand disease (AvWD) represents a rare, potentially severe and most likely underdiagnosed category of hemorrhagic syndromes determined by quantitative, qualitative or functional, nonhereditary, alterations of von Willebrand factor (vWF) that occur in the context of various underlying diseases. It is diagnosed mainly in adults, without any personal or familial history of bleeding. The etiopathogeny of AvWD is complex, marked by the intervention of multiple mechanisms, occuring in the evolution of neoplasia, autoimmune disorders, cardiovascular diseases and other conditions. The clinical and laboratory manifestations are similar to the congenital form with mucocutaneous hemorrhage in patients without bleeding history and demonstration of quantitative and/or functional anomalies of vWF. Treatment has two major objectives: control of bleeding and therapy of the underlying condition. As a practical illustration of the theoretical aspects we present 3 clinical cases of AvWD diagnosed in the Colţea Hospital Department of Hematology during the last 10 years.


Sign in / Sign up

Export Citation Format

Share Document